Activist pressure and new technology investment put H.B. Fuller in focus

H.B. Fuller (FUL) is drawing fresh investor attention after Ancora Holdings publicly opposed a potential acquisition of Advanced Medical Solutions Group and the company announced an investment in VerdaFresh oxygen barrier technology.

The recent 10.9% 7 day share price return and 6.9% 1 month share price return, against a 1 year total shareholder return of 18.8%, suggest momentum has picked up again after a softer 3 month patch.

If activism and new technology have you rethinking where growth could come from next, it might be worth scanning 20 top founder-led companies

With H.B. Fuller trading at US$64.08 versus an analyst price target of US$70.43 and an intrinsic value estimate that implies a premium, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 9% Undervalued

H.B. Fuller’s most followed narrative pegs fair value at $70.43, which sits above the last close at $64.08 and frames the recent share price recovery in a different light.

The company's strategic initiatives, such as optimizing the portfolio mix and streamlining the manufacturing cost structure, aim to drive the business toward a greater than 20% EBITDA margin target, potentially enhancing profitability and earnings. H.B. Fuller's efforts in leveraging its unique operating model to reduce exposure to currency fluctuations and tariffs are designed to maintain a competitive edge and support margin expansion, which can improve net margins and financial stability.

Want to understand why this narrative supports a higher value than today’s price? It leans heavily on steadier revenue growth, wider margins, and a future earnings multiple that differs from what the market is currently applying.

Result: Fair Value of $70.43 (UNDERVALUED)

However, this depends on solar headwinds and weak demand not lasting longer than analysts expect, and on raw material costs not putting renewed pressure on margins.

Another Angle On Valuation

The fair value narrative points to H.B. Fuller trading below a $70.43 target, yet our DCF model tells a different story. On that view, the stock at $64.08 sits above an estimate of future cash flow value of $59.74, which screens as overvalued. Which yardstick do you trust more for your own work?

Next Steps

After weighing the mixed signals in this story, it makes sense to check the underlying data yourself and decide quickly where you stand on both risk and upside. Start with 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If H.B. Fuller has sharpened your focus, do not stop here. Widening your watchlist now could be the edge that others miss later.

• Spot opportunities that combine quality and attractive pricing by checking 46 high quality undervalued stocks in just a few minutes.
• Prioritize resilience and sleep easier at night by scanning 64 resilient stocks with low risk scores before your next move.
• Get ahead of the crowd by reviewing the screener containing 22 high quality undiscovered gems that still fly under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.